EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Pulmonary Vascular Dysfunctions in Cystic Fibrosis

Jean-Pierre Amoakon iD, Goutham Mylavarapu iD, Raouf S Amin iD, Anjaparavanda P Naren

Physiology · 2024

DOI: 10.1152/physiol.00024.2023 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Physiology, 2024. Verfasst von Jean-Pierre Amoakon und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Systems Biology and Physiology, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Lung. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 163 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, American Heart Association (AHA), NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cystic fibrosis (CF) is an inherited disorder caused by a deleterious mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Given that the CFTR protein is a chloride channel expressed on a variety of cells throughout the human body, mutations in this gene impact several organs, particularly the lungs. For this very reason, research regarding CF disease and CFTR function has historically focused on the lung airway epithelium. Nevertheless, it was discovered more than two decades ago that CFTR is also expressed and functional on endothelial cells. Despite the great strides that have been made in understanding the role of CFTR in the airway epithelium, the role of CFTR in the endothelium remains unclear. Considering that the airway epithelium and endothelium work in tandem to allow gas exchange, it becomes very crucial to understand how a defective CFTR protein can impact the pulmonary vasculature and overall lung function. Fortunately, more recent research has been dedicated to elucidating the role of CFTR in the endothelium. As a result, several vascular dysfunctions associated with CF disease have come to light. Here, we summarize the current knowledge on pulmonary vascular dysfunctions in CF and discuss applicable therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorLungHumansAnimalsEndothelium, VascularMutationPulmonary Circulation

Stichwörter der Autor:innen

CFTRcystic fibrosisendothelial barrierendothelial cellspulmonary vasculature

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorCFTR protein, human

Autor:innen und Institutionen

  • Department of Systems Biology and Physiology, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States.
  • Division of Pulmonary Medicine and Critical Care, Cedars-Sinai Medical Center, Los Angeles, California, United States.
  • Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States.

ORCID-Profile: Jean-Pierre Amoakon, Goutham Mylavarapu, Raouf S Amin

Förderung

  • NIDDK NIH HHS
  • American Heart Association (AHA)
  • NHLBI NIH HHS
  • HHS | NIH | NHLBI | Division of Intramural Research (DIR)

Zitieren

APA

Amoakon, J. P., Mylavarapu, G., Amin, R. S., & Naren, A. P. (2024). Pulmonary Vascular Dysfunctions in Cystic Fibrosis. Physiology. https://doi.org/10.1152/physiol.00024.2023

Vancouver

Amoakon JP, Mylavarapu G, Amin RS, Naren AP. Pulmonary Vascular Dysfunctions in Cystic Fibrosis. Physiology. 2024. doi:10.1152/physiol.00024.2023

BibTeX
@article{Amoakon2024,
  author = {Amoakon, Jean-Pierre and Mylavarapu, Goutham and Amin, Raouf S and Naren, Anjaparavanda P},
  title = {Pulmonary Vascular Dysfunctions in Cystic Fibrosis},
  journal = {Physiology},
  year = {2024},
  doi = {10.1152/physiol.00024.2023}
}
Kostenlos starten →